J&J Invega Sustenna Patent Beats Teva, Viatris Appeals (Correct)

Johnson & Johnson fended off appeals by units of Teva Pharmaceutical Industries Ltd. and Viatris Inc. seeking to void a patent covering dosing regimens for the blockbuster schizophrenia drug Invega Sustenna, preserving its exclusivity until 2031.

Teva Pharmaceuticals USA Inc. and Viatris’ Mylan Laboratories Ltd. subsidiary failed to show the claimed dosing schedules in US Patent No. 9,439,906 would’ve been obvious to skilled researchers, Judge Richard Taranto wrote for a three-judge panel in an opinion issued Tuesday by the US Court of Appeals for the Federal Circuit.

The presumption that overlapping dosing ranges are usually obvious didn’t apply here, the panel ...